• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

横纹肌肉瘤中SWI/SNF亚基及抗癌基因BRM的沉默

The silencing of the SWI/SNF subunit and anticancer gene BRM in Rhabdoid tumors.

作者信息

Kahali Bhaskar, Yu Jinlong, Marquez Stefanie B, Thompson Kenneth W, Liang Shermi Y, Lu Li, Reisman David

机构信息

Division of Hematology/Oncology, Department of Medicine, University of Florida, Florida, USA.

出版信息

Oncotarget. 2014 May 30;5(10):3316-32. doi: 10.18632/oncotarget.1945.

DOI:10.18632/oncotarget.1945
PMID:24913006
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC4102812/
Abstract

Rhabdoid sarcomas are highly malignant tumors that usually occur in young children. A key to the genesis of this tumor is the mutational loss of the BAF47 gene as well as the widespread epigenetic suppression of other key anticancer genes. The BRM gene is one such epigenetically silenced gene in Rhabdoid tumors. This gene codes for an ATPase catalytic subunit that shifts histones and opens the chromatin. We show that BRM is an epigenetically silenced gene in 10/11 Rhabdoid cell lines and in 70% of Rhabdoid tumors. Moreover, BRM can be induced by BAF47 re-expression and by Flavopiridol. By selective shRNAi knockdown of BRM, we show that BRM re-expression is necessary for growth inhibition by BAF47 re-expression or Flavopiridol application. Similar to lung cancer cell lines, we found that HDAC3, HDAC9, MEF2D and GATA3 controlled BRM silencing and that HDAC9 was overexpressed in Rhabdoid cancer cell lines. In primary BRM-deficient Rhabdoid tumors, HDAC9 was also found to be highly overexpressed. Two insertional BRM promoter polymorphisms contribute to BRM silencing, but only the -1321 polymorphism correlated with BRM silencing in Rhabdoid cell lines. To determine how these polymorphisms were tied to BRM silencing, we conducted ChIP assays and found that both HDAC9 and MEF2D bound to the BRM promoter at or near these polymorphic sites. Using BRM promoter swap experiments, we indirectly showed that both HDAC9 and MEF2D bound to these polymorphic sites. Together, these data show that the mechanism of BRM silencing contributes to the pathogenesis of Rhabdoid tumors and appears to be conserved among tumor types.

摘要

横纹肌肉瘤是一种通常发生在幼儿身上的高度恶性肿瘤。该肿瘤发生的一个关键因素是BAF47基因的突变缺失以及其他关键抗癌基因的广泛表观遗传抑制。BRM基因就是横纹肌肉瘤中一个表观遗传沉默的基因。该基因编码一种ATP酶催化亚基,可使组蛋白移位并打开染色质。我们发现,BRM在11个横纹肌肉瘤细胞系中的10个以及70%的横纹肌肉瘤肿瘤中是表观遗传沉默基因。此外,BAF47的重新表达和黄酮哌啶醇可诱导BRM表达。通过选择性shRNAi敲低BRM,我们发现BRM的重新表达对于BAF47重新表达或应用黄酮哌啶醇抑制生长是必要的。与肺癌细胞系类似,我们发现HDAC3、HDAC9、MEF2D和GATA3控制BRM的沉默,并且HDAC9在横纹肌肉瘤癌细胞系中过表达。在原发性BRM缺陷的横纹肌肉瘤肿瘤中,也发现HDAC9高度过表达。BRM启动子的两个插入多态性导致BRM沉默,但只有-1321多态性与横纹肌肉瘤细胞系中的BRM沉默相关。为了确定这些多态性与BRM沉默的关联方式,我们进行了染色质免疫沉淀(ChIP)分析,发现HDAC9和MEF2D都在这些多态性位点或其附近与BRM启动子结合。通过BRM启动子交换实验,我们间接表明HDAC9和MEF2D都与这些多态性位点结合。这些数据共同表明,BRM沉默机制促成了横纹肌肉瘤的发病机制,并且在不同肿瘤类型中似乎是保守的。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/1046/4102812/d96aa78db26b/oncotarget-05-3316-g007.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/1046/4102812/7660f9722ee6/oncotarget-05-3316-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/1046/4102812/29641c7f5186/oncotarget-05-3316-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/1046/4102812/c27d55c41c72/oncotarget-05-3316-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/1046/4102812/f0b1f35e91ea/oncotarget-05-3316-g004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/1046/4102812/d70c9130bfc5/oncotarget-05-3316-g005.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/1046/4102812/8a61121f34a2/oncotarget-05-3316-g006.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/1046/4102812/d96aa78db26b/oncotarget-05-3316-g007.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/1046/4102812/7660f9722ee6/oncotarget-05-3316-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/1046/4102812/29641c7f5186/oncotarget-05-3316-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/1046/4102812/c27d55c41c72/oncotarget-05-3316-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/1046/4102812/f0b1f35e91ea/oncotarget-05-3316-g004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/1046/4102812/d70c9130bfc5/oncotarget-05-3316-g005.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/1046/4102812/8a61121f34a2/oncotarget-05-3316-g006.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/1046/4102812/d96aa78db26b/oncotarget-05-3316-g007.jpg

相似文献

1
The silencing of the SWI/SNF subunit and anticancer gene BRM in Rhabdoid tumors.横纹肌肉瘤中SWI/SNF亚基及抗癌基因BRM的沉默
Oncotarget. 2014 May 30;5(10):3316-32. doi: 10.18632/oncotarget.1945.
2
Identifying targets for the restoration and reactivation of BRM.确定 BRM 的恢复和重新激活的靶标。
Oncogene. 2014 Jan 30;33(5):653-64. doi: 10.1038/onc.2012.613. Epub 2013 Mar 25.
3
BRM Promoter Polymorphisms and Survival of Advanced Non-Small Cell Lung Cancer Patients in the Princess Margaret Cohort and CCTG BR.24 Trial.BRM启动子多态性与玛格丽特公主队列及CCTG BR.24试验中晚期非小细胞肺癌患者的生存情况
Clin Cancer Res. 2017 May 15;23(10):2460-2470. doi: 10.1158/1078-0432.CCR-16-1640. Epub 2016 Nov 8.
4
Alteration of hSNF5/INI1/BAF47 detected in rhabdoid cell lines and primary rhabdomyosarcomas but not Wilms' tumors.在横纹肌样细胞系和原发性横纹肌肉瘤中检测到hSNF5/INI1/BAF47的改变,但在肾母细胞瘤中未检测到。
Oncogene. 1999 Dec 9;18(52):7559-65. doi: 10.1038/sj.onc.1203168.
5
Dual loss of the SWI/SNF complex ATPases SMARCA4/BRG1 and SMARCA2/BRM is highly sensitive and specific for small cell carcinoma of the ovary, hypercalcaemic type.SWI/SNF复合物ATP酶SMARCA4/BRG1和SMARCA2/BRM的双重缺失对高钙血症型卵巢小细胞癌具有高度敏感性和特异性。
J Pathol. 2016 Feb;238(3):389-400. doi: 10.1002/path.4633. Epub 2015 Dec 21.
6
Frequent co-inactivation of the SWI/SNF subunits SMARCB1, SMARCA2 and PBRM1 in malignant rhabdoid tumours.恶性横纹肌样肿瘤中 SWI/SNF 亚基 SMARCB1、SMARCA2 和 PBRM1 的频繁共失活。
Histopathology. 2015 Jul;67(1):121-9. doi: 10.1111/his.12632. Epub 2015 Feb 5.
7
SWI/SNF chromatin-remodeling factors induce changes in DNA methylation to promote transcriptional activation.SWI/SNF染色质重塑因子诱导DNA甲基化变化以促进转录激活。
Cancer Res. 2005 May 1;65(9):3542-7. doi: 10.1158/0008-5472.CAN-04-3554.
8
SNF5 reexpression in malignant rhabdoid tumors regulates transcription of target genes by recruitment of SWI/SNF complexes and RNAPII to the transcription start site of their promoters.横纹肌肉瘤中 SNF5 的重新表达通过募集 SWI/SNF 复合物和 RNAPII 到其启动子的转录起始位点来调节靶基因的转录。
Mol Cancer Res. 2013 Mar;11(3):251-60. doi: 10.1158/1541-7786.MCR-12-0390. Epub 2013 Jan 30.
9
The Brm gene suppressed at the post-transcriptional level in various human cell lines is inducible by transient HDAC inhibitor treatment, which exhibits antioncogenic potential.在各种人类细胞系中,转录后水平受到抑制的Brm基因可通过短暂的组蛋白去乙酰化酶(HDAC)抑制剂处理诱导表达,该抑制剂具有抗癌潜力。
Oncogene. 2005 Aug 18;24(35):5471-81. doi: 10.1038/sj.onc.1208716.
10
SWI/SNF complex is essential for NRSF-mediated suppression of neuronal genes in human nonsmall cell lung carcinoma cell lines.SWI/SNF复合物对于NRSF介导的人类非小细胞肺癌细胞系中神经元基因的抑制至关重要。
Oncogene. 2006 Jan 19;25(3):470-9. doi: 10.1038/sj.onc.1209068.

引用本文的文献

1
Children's Oncology Group's 2023 blueprint for research: Renal tumors.儿童肿瘤学组 2023 年研究蓝图:肾肿瘤。
Pediatr Blood Cancer. 2023 Sep;70 Suppl 6(Suppl 6):e30586. doi: 10.1002/pbc.30586. Epub 2023 Jul 21.
2
(mis)-Targeting of SWI/SNF complex(es) in cancer.(错)靶向 SWI/SNF 复合物(es)治疗癌症。
Cancer Metastasis Rev. 2023 Jun;42(2):455-470. doi: 10.1007/s10555-023-10102-5. Epub 2023 Apr 24.
3
SMARCB1 Loss in Poorly Differentiated Chordomas Drives Tumor Progression.SMARCB1 缺失导致分化不良脊索瘤的肿瘤进展。

本文引用的文献

1
Two BRM promoter insertion polymorphisms increase the risk of early-stage upper aerodigestive tract cancers.两种BRM启动子插入多态性增加早期上呼吸消化道癌症风险。
Cancer Med. 2014 Apr;3(2):426-33. doi: 10.1002/cam4.201. Epub 2014 Feb 12.
2
The histone deacetylase inhibitor SAHA acts in synergism with fenretinide and doxorubicin to control growth of rhabdoid tumor cells.组蛋白去乙酰化酶抑制剂 SAHA 与芬维 A 酯和阿霉素协同作用,控制横纹肌瘤细胞的生长。
BMC Cancer. 2013 Jun 13;13:286. doi: 10.1186/1471-2407-13-286.
3
Discovery of BRM Targeted Therapies: Novel Reactivation of an Anti-cancer Gene.
Am J Pathol. 2023 Apr;193(4):456-473. doi: 10.1016/j.ajpath.2022.12.012. Epub 2023 Jan 16.
4
Whole-genome characterization of myoepithelial carcinomas of the soft tissue.软组织肌上皮癌的全基因组特征分析。
Cold Spring Harb Mol Case Stud. 2022 Dec 28;8(7). doi: 10.1101/mcs.a006227. Print 2022 Dec.
5
Epithelioid Sarcoma of Lumbar Spine: A Rare Mesenchymal Tumor Masquerading as Infection.腰椎上皮样肉瘤:一种伪装成感染的罕见间叶组织肿瘤。
Asian J Neurosurg. 2021 Feb 23;16(1):191-195. doi: 10.4103/ajns.AJNS_190_20. eCollection 2021 Jan-Mar.
6
Quis Custodiet Ipsos Custodes (Who Controls the Controllers)? Two Decades of Studies on HDAC9.谁来监管监管者?关于HDAC9的二十年研究
Life (Basel). 2021 Jan 27;11(2):90. doi: 10.3390/life11020090.
7
Small Cell Carcinoma of the Ovary, Hypercalcemic Type (SCCOHT) beyond Mutations: A Comprehensive Genomic Analysis.卵巢小细胞癌伴嗜血钙(SCCOHT),突变之外:全面的基因组分析。
Cells. 2020 Jun 19;9(6):1496. doi: 10.3390/cells9061496.
8
The SWI/SNF complex in cancer - biology, biomarkers and therapy.SWI/SNF 复合物在癌症中的作用——生物学、生物标志物和治疗。
Nat Rev Clin Oncol. 2020 Jul;17(7):435-448. doi: 10.1038/s41571-020-0357-3. Epub 2020 Apr 17.
9
High HDAC9 is associated with poor prognosis and promotes malignant progression in pancreatic ductal adenocarcinoma.高表达的组蛋白去乙酰化酶 9 与不良预后相关,并促进胰腺导管腺癌的恶性进展。
Mol Med Rep. 2020 Feb;21(2):822-832. doi: 10.3892/mmr.2019.10869. Epub 2019 Dec 6.
10
BRM: the core ATPase subunit of SWI/SNF chromatin-remodelling complex-a tumour suppressor or tumour-promoting factor?BRM:SWI/SNF 染色质重塑复合物的核心 ATP 酶亚基——抑癌因子还是促癌因子?
Epigenetics Chromatin. 2019 Nov 13;12(1):68. doi: 10.1186/s13072-019-0315-4.
BRM靶向疗法的发现:抗癌基因的新型激活
Lett Drug Des Discov. 2011 Jan 1;8(1):93-99. doi: 10.2174/157018011793663840.
4
Identifying targets for the restoration and reactivation of BRM.确定 BRM 的恢复和重新激活的靶标。
Oncogene. 2014 Jan 30;33(5):653-64. doi: 10.1038/onc.2012.613. Epub 2013 Mar 25.
5
Insertion/deletion polymorphisms in the promoter region of BRM contribute to risk of hepatocellular carcinoma in Chinese populations.BRM 启动子区域的插入/缺失多态性与中国人群肝癌的发病风险相关。
PLoS One. 2013;8(1):e55169. doi: 10.1371/journal.pone.0055169. Epub 2013 Jan 24.
6
Association of two BRM promoter polymorphisms with head and neck squamous cell carcinoma risk.BRM 启动子两个多态性与头颈部鳞状细胞癌风险的关联。
Carcinogenesis. 2013 May;34(5):1012-7. doi: 10.1093/carcin/bgt008. Epub 2013 Jan 15.
7
A remarkably simple genome underlies highly malignant pediatric rhabdoid cancers.高度恶性的小儿横纹肌肉瘤的基因组基础出人意料地简单。
J Clin Invest. 2012 Aug;122(8):2983-8. doi: 10.1172/JCI64400. Epub 2012 Jul 17.
8
Flavopiridol (L86 8275; NSC 649890), a new kinase inhibitor for tumor therapy.黄酮哌啶醇(L86 8275;NSC 649890),一种用于肿瘤治疗的新型激酶抑制剂。
Int J Oncol. 1996 Dec;9(6):1143-68. doi: 10.3892/ijo.9.6.1143.
9
Two novel BRM insertion promoter sequence variants are associated with loss of BRM expression and lung cancer risk.两个新型 BRM 插入启动子序列变异与 BRM 表达缺失和肺癌风险相关。
Oncogene. 2011 Jul 21;30(29):3295-304. doi: 10.1038/onc.2011.81. Epub 2011 Apr 11.
10
Pharmacologic reversal of epigenetic silencing of the anticancer protein BRM: a novel targeted treatment strategy.药物逆转抑癌蛋白 BRM 的表观遗传沉默:一种新的靶向治疗策略。
Oncogene. 2011 Jul 21;30(29):3289-94. doi: 10.1038/onc.2011.80. Epub 2011 Apr 11.